This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q3 Earnings Meet Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 30.61% and 46.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 3.92% and 45.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.27% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 20% and 70.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 2.86% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 26.32% and 5.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Solid Biosciences Inc. (SLDB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15% and 9.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ThermoGenesis Holdings, Inc. (THMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
ThermoGenesis Holdings, Inc. (THMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 31st
by Zacks Equity Research
AMWD, CYTK, STIM, OLLI, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on August 31, 2021.
ThermoGenesis Holdings, Inc. (THMO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -111.11% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ThermoGenesis Holdings, Inc. (THMO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
ThermoGenesis Holdings, Inc. (THMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 2nd
by Zacks Equity Research
PDCO, SABR, JRSH, UPWK, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2021
New Strong Sell Stocks for December 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for November 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Stock Market News for Aug 25, 2020
by Zacks Equity Research
The S&P 500 and the Nasdaq hit an all-time high on Monday after news of a potential coronavirus treatment lifted investors' sentiment.
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
by Zacks Equity Research
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
5 Stocks With Recent Price Strength Amid Disappointing Data
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ThermoGenesis Holdings, Inc. (THMO) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in ThermoGenesis Holdings, Inc. (THMO).